Company profile: Iama Therapeutics
1.1 - Company Overview
Company description
- Provider of novel neuroscience therapeutics for pediatric brain disorders, advancing drug discovery to address unmet needs; lead candidate IAMA-6 is an orally administered small molecule targeting NKCC1-associated neuronal hyperexcitability, currently in Phase 1 clinical trials for autism and epilepsy.
Products and services
- Neuroscience Drug Discovery: A pediatric-focused research program that architects novel medicines addressing unmet medical needs in the brain, advancing therapies for children suffering from neurological conditions and their families
- Novel Therapeutics Development: A brain-targeted development effort that engineers new therapeutics to make a difference for children with brain disorders, producing therapeutic products for neurological conditions
- IAMA-6: A clinical-stage, orally administered small-molecule therapeutic that targets NKCC1-associated neuronal hyperexcitability, currently in Phase 1 clinical trials for treating autism and epilepsy
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Iama Therapeutics
Sequent Medical
HQ: United States
Website
- Description: Provider of innovative catheter-based neurovascular technologies, including proprietary Microbraid™ technology used to create the WEB™ Aneurysm Embolization System for the treatment of neurovascular diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sequent Medical company profile →
BlackThorn Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage neurobehavioral health, pioneering the next generation of artificial intelligence.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BlackThorn Therapeutics company profile →
InNeuroCo
HQ: United States
Website
- Description: Provider of complex catheter solutions for neurovascular applications, delivering design and development of medical devices, ISO-certified contract manufacturing and assembly for the neurovascular industry, and regulatory submissions support with over 20 submissions in the US, Europe, and Asia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InNeuroCo company profile →
EndoTex
HQ: United States
Website
- Description: Provider of less-invasive medical devices for use in the vascular system, offering solutions for treating carotid artery disease. Focused on development and manufacturing; founded in 1995 and based in Cupertino, California.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EndoTex company profile →
Muna Therapeutics
HQ: Denmark
Website
- Description: Provider of biopharmaceutical therapies and discovery platforms to slow or stop neurodegenerative diseases including Alzheimer’s, Parkinson’s, Frontotemporal Dementia, and Multiple Sclerosis. Programs include TREM2 agonism for early-stage Alzheimer’s, Kv1.3 blockade for Parkinson’s and MS, and MiND-MAP, an all-in-human target discovery and validation platform using single cell spatial multi-omics in patient samples.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Muna Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Iama Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Iama Therapeutics
2.2 - Growth funds investing in similar companies to Iama Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Iama Therapeutics
4.2 - Public trading comparable groups for Iama Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →